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Abstract/Summary 1 
Introduction: This study investigated the occurrence of rheumatic conditions (RCs) in 2 
a psoriasis(PSO)-dedicated dermatological clinic. 3 
Methods: PSO subjects with musculo-skeletal discomfort, and/or carrying signs 4 
(articular/systemic, even asymptomatic) of RCs; and/or suffering flares of previously 5 
established psoriatic arthritis (PsA) were referred to rheumatologist for evaluation. 6 
Laboratory tests/imaging were performed as needed. Categorization adhered to RCs 7 
classification endorsed by the Italian Society of Rheumatology. 8 
Results: Of 1200 psoriatic subjects, 277 (23.1%) were enrolled (146 females). The 9 
mean age was 55.7 years (range 21-81), PSO duration was 13.5 years (range 0-62). 10 
Thirty-seven patients (13.4%) were asymptomatic. 11 
On average, 92 (7.6%) patients/year were evaluated, of whom 79.4% näive to 12 
rheumatological consultations (NRC). Osteoarthritis (OA) and PsA (isolated or 13 
combined) showed the highest prevalence, with 156 (56.3%) and 110 cases (39.7%), 14 
respectively. Among NRC subjects, the mean PsA annual incidence was 29.5% 15 
(standard error of the mean ± 5.4%). Other RCs, isolated or associated with PsA/OA, 16 
were diagnosed in 31 cases (11.2%). Thirty-two subjects (11.5%) had arthralgias, 20 17 
of whom due to congenital/mechanical disorders, the remaining were unclassifiable. 18 
Conclusions: The largest part (88.5%) of PSO subjects referred to rheumatologist 19 
showed some RCs. On annual basis, 29.5% of näive enrolled patients were 20 
diagnosed as PsA. 21 
22 
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Introduction 1 
Psoriatic arthritis (PsA) is a peculiar psoriasis (PSO)-associated condition, with 2 
prevalence and annual incidence among psoriatic subjects of 6-42% and 1.87%, 3 
respectively[5]. Up to 53% of PSO cases complain of musculo-skeletal 4 
symptoms[15], while the co-occurrence of other diseases like systemic auto-immune 5 
connective tissues diseases (SACDs) with PSO remains poorly investigated[4]. 6 
Evaluation of PSO patients attending dedicated dermatological clinics seems a 7 
reasonable mean to investigate the relationships between PSO and rheumatic 8 
diseases, although such approach may be troublesome in daily dermatological 9 
practice[14]. 10 
The aim of this study was to report the epidemiological results (the overall prevalence 11 
of rheumatic conditions, with a focus on prevalence and incidence of PsA) of the 12 
dermatologist-rheumatologist cooperation in a dermatological clinic appointed to 13 
diagnosis and treatment of PSO. 14 
15 
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Methods 1 
Study design 2 
This was an observational, non interventional study on PSO patients, followed up in 3 
the dedicated clinic of Dermatology Department at Fondazione IRCCS Ca’ Granda 4 
Ospedale Maggiore Policlinico, in Milano (Italy). PSO Patients are referred to this 5 
clinic from both primary care (dermatological, general practices) and other hospitals. 6 
This should prevent selection biases in terms of PSO severity and misdiagnosis. 7 
Since July 2008, a regular cooperation between rheumatologists and dermatologists 8 
was established. 9 
Data reported in this paper were collected from July 2008 to July 2011, in 10 
consecutive subjects, according to the Declaration of Helsinki. All patients gave their 11 
informed consent before enrolment. 12 
In order to check for misinterpreted PsA, candidates previously diagnosed as having 13 
PsA had their clinical notes completely reviewed. 14 
Inclusion criteria 15 
The patients enrolled were adults (older than 18 years), with established diagnosis of 16 
PSO (clinical or, if needed, histological), without limitations regarding any form or 17 
onset age of PSO. 18 
Aiming to maximize sensitivity and decrease selection biases, all subjects followed 19 
up in the clinic were systematically interviewed and assessed, then referred to 20 
rheumatological evaluation whether they satisfied at least one of the following 21 
criteria: 22 
a) presence of musculo-skeletal discomfort or joint swelling (current or past, 23 
spontaneously referred or elicited by the interviewing dermatologists); 24 
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b) presence, in dermatologist’s opinion, of inflammatory signs (articular or not), 1 
limping and/or joint deformities, even in absence of symptoms; 2 
c) flare of previously established PsA or other rheumatic disease. 3 
Any current, past or experimental therapeutic regimen for PSO was allowed. 4 
Although screening questionnaires are not extensively validated or compared “head 5 
to head”[8], patients were encouraged to fill in the psoriatic arthritis screening 6 
evaluation (PASE) questionnaire[9]. To maximize sensitivity, however, the results did 7 
not represent a cut-off criteria for enrolment. 8 
Exclusion criteria 9 
Subjects with psoriasis-like conditions (e. g. seborrhoeic dermatitis, eczema), were 10 
not eligible. 11 
Data collection 12 
Consensus core set domains for PsA[7] were used for data collection purposes. At 13 
enrolment, the psoriasis area and severity index (PASI) score[6] was calculated if 14 
enough skin was involved. Dermatologists and rheumatologists actively sought nail 15 
psoriasis (current, past). 16 
Personal histories were carefully evaluated, along with previous medical reports 17 
(particularly synovial fluid analysis/biopsies). The presence of fatigue, morning 18 
stiffness and inflammatory back pain (defined according to Assessment of 19 
SpondyloArthritis International Society criteria[10]) were recorded. 20 
Rheumatological examinations, performed by the same observer (GDM), aimed to 21 
disclose signs of musculo-skeletal inflammation (current, past, peripheral, axial), 22 
seeking for joint swelling/pain, dactylitis, pitting edema, entheseal soft 23 
swelling/tenderness, damaged/deformed joints, loss of articular motion/ankylosis, 24 
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subcutaneous nodules. Rheumatological counts (joints, dactylitic fingers/toes, tender 1 
entheses, tender points) were performed as well. 2 
Signs of SACDs such as erythema nodosum, scleroderma, rashes (malar “butterfly” 3 
rash, Gottron’s papules), palpable purpura or ulcers (oral, genital, cutaneous) were 4 
routinely sought. 5 
Laboratory tests such as blood cells count, erythrocyte sedimentation rate, C-reactive 6 
protein, rheumatoid factor (RF), anti-citrullinated peptide/proteins antibodies (ACPA), 7 
anti-nuclear antibodies (ANA), if clinically necessary, were performed according to 8 
widely accepted methods (Westergren, nephelometry, ELISA and immuno-9 
fluorescence, respectively). Results were considered altered when above the upper 10 
limit of normal, according to local laboratories values. 11 
Plain radiographs of painful/damaged sites were performed when clinically needed. 12 
Advanced imaging techniques (bone scans, computed tomography scans, nuclear 13 
magnetic resonances or ultrasonography) were performed in clinically selected 14 
cases. 15 
Case definition of rheumatic disease 16 
Patients were categorised according to the classification of rheumatic diseases 17 
endorsed by the Italian Society for Rheumatology (SIR) [12]. Briefly, rheumatic 18 
conditions are defined as: primarily musculo-skeletal (degenerative, inflammatory, 19 
infectious, metabolic); SACDs (e. g. systemic lupus erythematosus); extra-articular 20 
(e. g. fibromyalgia); bone diseases (e. g. osteoporosis); congenital/mechanical 21 
disorders (benign hypermobility syndrome, idiopathic scoliosis, flat feet); neoplasms 22 
(particularly those affecting synovium); others. 23 
Case definition of PsA 24 
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Like several rheumatic conditions, PsA lacks of biological markers. Diagnosis relies 1 
on the interpretation of clinical, laboratory and imaging findings by a rheumatologist 2 
well-trained in the field of spondylo-arthropathies. In this study PsA cases were 3 
identified through expert opinion. For classification purposes, we adopted Vasey-4 
Espinoza[13] and the ClASsification criteria for Psoriatic ARthritis (CASPAR)[11]. 5 
Other inflammatory conditions of joints, not attributable to well defined entities [like 6 
rheumatoid arthritis (RA)], were classified as undifferentiated arthritis (UA). 7 
Statistical analysis 8 
Continuous variables are described through means, medians, standard deviations 9 
(SD), standard errors of the means (SEM), absolute and inter-quartile (IQ) ranges. 10 
For the other variables, frequency tables, prevalences and incidences are reported. 11 
Confidence intervals (CI) were set on 95%. 12 
For appropriate incidence calculation, subjects with PsA onset concurrent with PSO 13 
(at the same time or up to one year following PSO diagnosis) were excluded from 14 
this peculiar analysis. 15 
To compare continuous variables we adopted Student’s t test or Mann-Whitney’s U 16 
statistic (where appropriate). Other differences were tested through ぬ2 test or Fisher’s 17 
exact test. Statistical level of significance was set on 0.01. 18 
The software used was Epi infoTM, version 3.5.3, year 2011 (Centers for Disease 19 
Control and Prevention, Atlanta, GA, USA). 20 
21 
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Results 1 
Demographic and clinical characteristics 2 
The dermatological clinic involved in this study follows up about 1200 PSO patients, 3 
who are on average middle-aged, with overall mild skin activity (table 1). By July 4 
2011, 277 subjects (23.1%) were included in our study. Among these, 273 (98.6%) 5 
had some musculo-skeletal discomfort. While 240 (86.6%) reported arthralgias or 6 
back pain, 37 (13.4%) were symptom-less.  Table 1 shows similar demographic and 7 
clinical characteristics between patients enrolled and the remaining PSO subjects, 8 
except for a slight, non significant difference in gender ratio. 9 
TABLE 1 AND FIGURE 1 TO BE INSERTED HERE 10 
Figure 1 depicts the proportions of different PSO forms among the 277 enrolled 11 
patients. Although plaque PSO was abundant, 6 patients (2.2%) had isolated nail 12 
involvement. All pustular PSO were localised, while no case of erythrodermia 13 
psoriatica was noted during this study among enrolled subjects. 14 
At enrolment, 199 patients (71.8%) were receiving only topical or oral retinoid 15 
therapies. The remaining 78 were on systemic treatment (cyclosporine A, 16 
methotrexate, TNFg-inhibitors or systemic steroids). About previous therapies, 120 17 
patients (43.3% of enrolled subjects) received at least one of the systemic drugs 18 
listed above and/or other biologics such as alefacept or efalizumab. These figures 19 
were comparable to those from the remaining psoriatic patients followed up in our 20 
clinic (figure 2), without statistical difference (a trend toward difference concerned 21 
only TNFg-inhibitors: ぬ2 3.8, p value 0.049). 22 
FIGURE 2 TO BE INSERTED HERE 23 
Enrolment rates 24 
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On average, 92 subjects were enrolled each year (88 between July 2008-June 2009, 1 
97 between July 2009-June 2010, 92 between July 2010-July 2011). Concurrently, 2 
the mean number of enrolled patients näive to rheumatological evaluations was 3 
73±4.0 SEM (79.4% of those enrolled each year). 4 
The diagram flow-chart of the enrolment procedures and detailed results is reported 5 
in figure 3. 6 
The rheumatic diseases disclosed among enrolled patients are detailed in table 2. 7 
FIGURE 3 AND TABLE 2 TO BE INSERTED HERE 8 
a) Degenerative disorders 9 
The largest part of enrolled patients had degenerative musculo-skeletal disorders, 10 
especially osteoarthritis (OA). Such condition was found alone or associated with 11 
PsA (e. g. secondary forms or primary forms concomitant with PsA). Overall, 47 12 
cases of degenerative diseases overlapped with PsA, (42.7% of PsA). 13 
Diffuse Idiopathic Skeletal Hyperostosis was a frequent cause of long-standing 14 
reduced spinal mobility. The cooperative approach adopted in this study facilitated 15 
the appropriate classification of such ankylosing degenerative disorder of the spine. 16 
b) Inflammatory musculo-skeletal disorders 17 
Extensive review of clinical notes retrieved 124 subjects (10.3% of PSO patients of 18 
the clinic) already diagnosed as PsA before enrolment. Among the 277 enrolled 19 
patients, 57 had already received the diagnosis of PsA, 45 of whom (78.9%) were 20 
confirmed after enrolment. Consequently, in the clinic population, PsA cases 21 
decreased to 112 (overall prevalence of 9.3%, 95% CI 9.25-9.35) before the 22 
beginning of enrolment procedures. 23 
As shown in table 3, out of 110 PsA cases collected in our study by July 2011, 65 24 
(59.1%) were newly diagnosed because of enrolment, 31 of whom (47.7%) suffered 25 
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the clinical onset of PsA within one year before enrolment. It has to be stressed that 1 
14 of newly diagnosed PsA (21.5%) did not show peculiar inflammatory symptoms, 2 
or were asymptomatic. Forty-one enrolled subjects (all näive to rheumatological 3 
evaluations) agreed to fill in the PASE questionnaire (13 PsA, 28 non-PsA). Among 4 
PsA, 4 (30.8%) scored ≥47 (the original cut off value [6]), while 8 non-PsA (28.6%) 5 
reported similar results. 6 
TABLE 3 TO BE INSERTED HERE 7 
Applying classification criteria, 109 PsA subjects (99.1%) satisfied the Vasey-8 
Espinoza criteria, while 99 (90%) satisfied CASPAR criteria. Interestingly, the single 9 
PsA case not satisfying Vasey-Espinoza rule had a CASPAR score of 3. 10 
Newly diagnosed PsA cases already on systemic treatment at the time of enrolment 11 
did not show atypical clinical presentation, even those 8 (12.3%) on TNFg-inhibitors. 12 
Cases of PsA onset concurrent with PSO onset were 5 (representing 2.8% of the 13 
whole clinic population and 4.5% of PsA among the enrolled subjects). On average, 14 
21 subjects were incident cases of PsA each year (20, 27 and 18 respectively). On 15 
annual basis, the mean incidence of PsA in the clinic was 1.7% (SEM ±0.2%). 16 
However, considering those enrolled subjects näive to rheumatological evaluations, 17 
the mean incidence arose to 29.5% (SEM ±2.7%). 18 
By July 2011, PsA cases increased to 177 in the whole clinic population, yielding a 19 
cumulative prevalence of 14.7% (95% CI 12.7-16.7). 20 
Cases of chronic arthritis of uncertain origin (despite every investigation adopted) 21 
were infrequent among our patients. Such subjects would probably require a longer 22 
follow up to be properly classified. 23 
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One UA case overlapped with giant cells synovial tumour localised in the third right 1 
finger flexor tendon, but the patient had a bone erosion of the fifth meta-tarsal bone, 2 
suggestive of RA. 3 
c) Auto-immune connective tissues disorders and vasculitidies 4 
Polymyalgia rheumatica (a typical vasculitis of the elderly) was found in only one 5 
patient. Although ANA were positive in 11.9% of enrolled subjects (see below), 6 
SACDs cases were rare. The single case (0.4% among enrolled subjects) of 7 
Sarcoidosis ascertained in our series was enrolled because of finger flexor 8 
contraction due to tenosynovitis. Sarcoidosis was accidentally disclosed (after 9 
thoracic lymphonodal biopsy due to tuberculosis screening procedures). The 10 
cutaneous lesions of this patient were truly psoriatic and signs of erythema nodosum 11 
were never reported or found. 12 
d) Metabolic musculo-skeletal disorders 13 
Out of the 4 osteoporotic enrolled cases, 2 were post-menopausal and 2 senile. The 14 
2 patients suffering from reflex sympathetic dystrophy had both OA and were 15 
enrolled because they were complaining of a painful, swollen ankle. 16 
Out of 3 gouty subjects, one was enrolled because of subacute wrist arthritis. This 17 
patient was classified, after appropriate investigations (synovial fluid analysis, plain 18 
radiographies), as having PsA. The previous arthritic attack, ten years earlier, 19 
occurred in the left first metatarso-phalangeal joint (podagra) and was confirmed as 20 
gout through synovial fluid analysis report. Therefore, gout overlapped with PsA in 21 
0.9% of cases. 22 
e) Miscellaneous rheumatic diseases 23 
Extra-articular disorders were frequently diagnosed. Fibromyalgia overlapped with 24 
PsA in 6 cases (5.4%). Such painful condition, as well as symptomatic idiopathic 25 
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scoliosis, flat feet or hip dysplasia, is not associated with objective inflammatory 1 
signs. Considering that the patients often reported symptoms that may simulate 2 
inflammatory disorders (e. g. prolonged morning stiffness), advanced imaging 3 
techniques (ultrasound tomography and nuclear magnetic resonance) were needed 4 
in order to classify such cases appropriately as non-inflammatory. 5 
The occurrence of Raynaud’s phenomenon also implied appropriate investigations, 6 
aimed to disclose SACDs. In all the patients affected by that vascular disorder, no 7 
abnormalities were found. 8 
As well as SACDs, neoplasms of the musculo-skeletal system were also infrequently 9 
found. Although such conditions are often clinically well characterized, peculiar 10 
localizations (e. g. the joints of the hands) may complicate the differential diagnosis. 11 
In our case, surgical biopsy of the finger was needed. 12 
f) Unclassifiable, non-inflammatory arthralgias 13 
These cases, despite of any investigation, could not be classified. No single 14 
laboratory test or imaging technique revealed evidence of inflammatory lesions. After 15 
three years of follow up, none of these patients could be classified otherwise. 16 
Laboratory tests findings 17 
No enrolled patient had drops in blood cells count. Four PsA were RF positive, all of 18 
whom with oligo-arthritis and psoriatic nails (one case showed involvement of distal 19 
inter-phalangeal joints of the hands). None of these subjects had radiographic 20 
erosions suggestive of RA. 21 
A title of ≥1:160 was found in 22 (66%) of the 33 ANA-positive enrolled subjects. 22 
Such auto-antibodies correlated with concurrent TNFg-inhibition therapies (7 subjects 23 
among ANA-positive versus 2 among negatives; odds ratio12.6, CI 2.5-64.6; ぬ2=11, p 24 
value <0.001). 25 
26 
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Discussion 1 
To our knowledge, previous reports investigating rheumatic conditions among PSO 2 
subjects mainly focused on inflammatory joints manifestations[1] or SACDs [4] in a 3 
distinctive fashion. 4 
Overall, the enrolment strategy adopted in this study (direct identification, by the 5 
dermatologist, of PSO patients in whom rheumatological referral could be useful) was 6 
straightforward and little time consuming, allowing the detection of several rheumatic 7 
disorders. Further, the systematic application, to each subject cared at our centre, of 8 
interviews and physical inspection by dermatologists allowed us to enrol a substantial 9 
proportion (13.4%) of asymptomatic patients. 10 
Nevertheless, the most commonly referred subjects were those who complained of 11 
musculo-skeletal symptoms (mainly pain), occurring on average at the end of the fifth 12 
decade of life. Although this phenomena may be reported by up to 53% of all 13 
psoriatic patients[15], its fair attribution to PsA, OA, UA or Fibromyalgia may be 14 
difficult[14]. Further, our results highlight a consistent overlap of several rheumatic 15 
diseases (inflammatory and others). 16 
Degenerative conditions were highly prevalent among enrolled subjects. Although 17 
our series shows demographic characteristics similar to others described 18 
elsewhere[3], such finding was expected, given the mean age of patients enrolled. It 19 
seems difficult to establish whether, in PSO subjects, degenerative conditions are 20 
more frequent than in general population. The medical literature, however, does 21 
report data [14,15] similar to ours. 22 
PsA was the second more prevalent musculo-skeletal condition. Although in our 23 
clinic the mean annual incidence per 100 PSO cases was 1.7% (the same reported 24 
in another study[5]), each year 29.5% of those näive subjects eligible for 25 
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rheumatological consultation were diagnosed as PsA. Our referral strategy allowed 1 
us to disclose several new (incident) PsA cases, 47.7% of whom classifiable as early 2 
forms (clinical onset within one year) already carrying radiological damage in 32.3% 3 
of cases. 4 
Considering the mild severity of cutaneous disease in our subjects, these findings 5 
seem particularly valuable, above all when compared to other publications[3]. Such 6 
characteristic was confirmed by the frequency of topical therapies. Nevertheless, 7 
some cases of PsA might have been hidden by systemic therapies (e. g. 8 
methotrexate). 9 
Metabolic disorders were uncommon, although osteoporosis could have been 10 
strongly underestimated because bone densitometry was not systematically 11 
performed. 12 
Auto-antibodies were infrequently detected (ACPA were less frequent than previously 13 
reported in PSO[2]), or related to anti-TNFg therapies. The only two cases of 14 
Raynaud’s phenomenon were not associated to SACDs, and we diagnosed a single 15 
case of Sarcoidosis. Our data seem to support other findings [4] about the infrequent 16 
co-occurrence of SACDs and PSO, although such issue requires further studies. 17 
It has to be stressed that several enrolled patients (11.5%) suffered from musculo-18 
skeletal discomfort due to mechanical conditions or unexplained arthralgias. Such 19 
cases required more diagnostic investigations (particularly advanced imaging 20 
techniques) and seemed at greater risk of PsA misdiagnosis or inappropriate 21 
exposure to immuno-suppressive drugs. 22 
This study has some limitations. The number of enrolled subjects (277 patients) was 23 
not large enough to disclose rare, concomitant diseases (<0.1%). Further, patients 24 
scarcely symptomatic may have been missed, especially among those not referred 25 
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by dermatologists. Indeed, although this study was not designed to report about the 1 
adequacy of referral criteria, the authors trust that the inclusion strategy, the 2 
systematic approach, the close cooperation between rheumatologists and 3 
dermatologists and the length of the observation period (37 months) should have 4 
maximized the sensitivity of our results. Finally, since laboratory and imaging 5 
investigations were performed, when indicated, only among enrolled patients, several 6 
conditions might have been missed. 7 
In conclusion, rheumatic disorders are frequent in PSO subjects. Although mostly 8 
resulted non-inflammatory, 29.5% of enrolled subjects näive to rheumatological 9 
evaluation had PsA. Cooperative approaches between dermatologists and 10 
rheumatologists, as the one described, seem to be a powerful tool for detection of 11 
early PsA and for management of rheumatic disorders in PSO patients. 12 
13 
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Table 1 demographic and clinical characteristics of the subjects enrolled in the 
present study (SE), compared to the remaining psoriatic population (RPP). Psoriatic 
patients cared at our clinic are 1200. 
 SE (n 277) 
RPP 
(n 933) p value 
Sex (M/F); ratio 131/146; 0.9 489/444; 1.1 0.15 
Current age in years, mean (SD) 55.7 (13) 55.3 (14.6) 0.68 
PASI score, median (IQR) 3.1 (1.2-5.8) 3 (1.4-6) 0.76 
Subjects with PASI score ≥ 10, number (%) 34 (12.3) 104 (11.1) 0.68 
Subjects with nail psoriasis, number (%) 116 (41.9) 419 (44.9) 0.41 
Age at psoriasis onset in years, mean (SD) 42.1 (17.1) 41.6 (17.3) 0.67 
Interval between psoriasis onset and current 
age in years, median (IQR) 10 (4-18) 10 (4-19.2) 0.75 
Age at musculo-skeletal symptoms onset in 
years, mean (SD) 50.1 (13) NA / 
M = male; F = female; NS = not significant; SD = standard deviation; PASI = 
Psoriasis Area and Surface Index; IQR = inter-quartile range; NA = not assessed 
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Table 2 Frequencies of rheumatic conditions among the 277 subjects enrolled. 
The disorders enlisted may overlap unless specified(§) 
 Number of cases (%) 
a) Degenerative musculo-skeletal disorders  
 Osteoarthritis 156 (56.3) 
 Diffuse idiopathic skeletal hyperostosis 16 (5.8) 
 Shoulder peri-articular degeneration 10 (3.6) 
 Hip peri-articular degeneration 2 (0.7) 
b)Inflammatory musculo-skeletal disorders  
 Psoriatic Arthritis 110 (39.7) 
 Undifferentiated arthritis 2 (0.7) 
c) Auto-immune connective tissues disorders/vasculitidies  
 Polymyalgia rheumatica 1 (0.4) 
 Sarcoidosis§ 1 (0.4) 
d) Metabolic musculo-skeletal disorders  
 Osteoporosis (post-menopausal or senile) 4 (1.4) 
 Gout 3 (1.1) 
 Chondrocalcinosis 3 (1.1) 
 Reflex sympathetic dystrophy 2 (0.7) 
 Emochromatosis 1 (0.4) 
e) Miscellaneous rheumatic diseases  
 Arthralgia secondary to congenital/mechanical 
conditions§* 
20 (7.2) 
 Fibromyalgia 15 (5.4) 
 Idiopathic Raynaud’s phenomenon 2 (0.7) 
 Giant cells synovial tumour 1 (0.4) 
f) Unclassifiable, non-inflammatory arthralgias§ 12 (4.3) 
*such as hypermobility syndrome, idiopathic scoliosis, flat feet, hip dysplasia 
(congenital or developmental) 
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Table 3 demographic and clinical characteristics of previously established Psoriatic 
Arthritis (PE PsA), compared to newly diagnosed PsA (ND PsA) 





Gender (M/F); ratio 27/18; 1.5 38/27;  1.4 0.97 
Current age in years, mean (SD) 53.1 (14.2) 53.4 (13.9) 0.92 
PASI score, median (IQR) 4.7 (2.4-8) 4.2 (2-6.5) 0.4 
Subjects with PASI score ≥ 10, number (%) 10 (22.2) 10 (15.3) 0.5 
Subjects with nail psoriasis, number (%) 23 (51.1) 26 (40) 0.33 
Age at psoriasis onset in years, mean (SD) 35.8 (17) 41.5 (15.7) 0.07 
Interval between psoriasis onset and current age 
in years, median (IQR) 13 (8-24) 9 (4-16) 0.006 
Age at musculo-skeletal symptoms onset in 
years, mean (SD) 43.6 (13.2) 50.4 (13.9) 0.011 
Onset of PsA ≤ 1 year since enrolment 6 (13.3) 31 (47.7) <0.001 
Onset of PsA ≥ 5 years since enrolment 21 (46.7) 5 (7.7) <0.001 
Peripheral oligo-arthritis 17 (37.8) 40 (61.5) 0.02 
Peripheral poly-arthritis 20 (44.4) 14 (21.5) 0.019 
Axial PsA 12 (26.7) 5 (7.7) 0.015 
Clinical articular damage due to PsA 20 (44.4) 16 (24.6) 0.049 
Radiological damage due to PsA 21 (46.7) 21 (32.3) 0.18 
Subjects with altered ESR, number (%) 13 (28.9) 30 (46.1) 0.1 
Subjects with altered CRP, number (%) 16 (35.6) 23 (35.4) 0.85 
Subjects with positive RF, number (%) 1 (2.2) 3 (4.6) 0.88 
Subjects with positive ACPA, number (%) 0 (0) 1 (1.5) 0.85 
Subjects on systemic treatments active on PsA* 25 (55.5) 14 (21.5) <0.001 
M = male; F = female; NS = not significant; SD = standard deviation; PASI = 
Psoriasis Area and Surface Index; IQR = inter-quartile range; ESR = erythrocyte 
sedimentation rate; CRP = C-reactive protein; RF = rheumatoid factor; ACPA = anti-
citrullinated peptides/proteins antibodies 
 
*Such treatments are cyclosporine A, methotrexate, TNFg-inhibitors 
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Figures and related legends 1 
 2 
Figure 1 3 
 4 
details about the forms of psoriasis diagnosed among the enrolled subjects. No 5 
patient presented erythrodermia psoriatica during the observation period (37 6 
months). 7 
8 
Page 23 of 25 
Author: G De Marco 
 
 1 
Figure 2 2 
 3 
Dermatological therapies, ever done. Enrolled patients (n 277) are depicted in black, 4 
the remaining psoriatic subjects followed up in the clinic (n 933) are depicted in grey. 5 
Topical therapies are corticosteroids or vitamin D derivatives or salicylic acid in form 6 
of creams, ointments or lotions; systemic therapies are oral retinoids or oral steroids, 7 
cyclosporine A, methotrexate, mophetil mycophenolate; other biologics are alefacept 8 
or efalizumab. 9 
10 
Page 24 of 25 
Author: G De Marco 
 
 1 
Figure 3 2 
 3 
Flow chart diagram of the study. The outcomes of the identification process, stratified 4 
by the years of enrollment, are illustrated. 5 
PsA = psoriatic arthritis 6 
7 
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Abbreviations and acronyms list 1 
ACPA = anti-citrullinated peptide/proteins antibodies 2 
ANA = anti-nuclear antibodies 3 
CASPAR = ClASsification criteria for Psoriatic Arthritis criteria 4 
OA = osteoarthritis 5 
PASE = psoriatic arthritis screening evaluation questionnaire 6 
PASI = psoriasis area and severity index 7 
PsA = psoriatic arthritis 8 
PSO = psoriasis 9 
RF = rheumatoid factor 10 
RA = rheumatoid arthritis 11 
SACDs = systemic auto-immune connective tissues diseases 12 
SIR = the Italian Society for Rheumatology 13 
UA = undifferentiated arthritis 14 
